Narrative review / 2020
NAD+ boosting via the precursor niacin shows potential as a treatment strategy for mitochondrial myopathy in humans.
This commentary highlights findings by Pirinen et al. (2020) regarding NAD+ homeostasis in mitochondrial myopathy. The referenced work demonstrates that disruption in NAD+ homeostasis is a key component of the pathogenesis of mitochondrial myopathy in humans. This disruption can be targeted by administering the NAD+ precursor niacin, identifying NAD+ boosting as a potential therapeutic approach.
- Study type
- Commentary
- Who was studied
- Mitochondrial myopathy patients
- What was measured
- Mitochondrial myopathy pathogenesis and NAD+ boosting
THE PAPER
Of Mice and Men: NAD+ Boosting with Niacin Provides Hope for Mitochondrial Myopathy Patients.
Chini EN. Cell Metab, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.